

REVIEW ARTICLE

CURRENT CONCEPTS

Chronic Constipation

Anthony Lembo, M.D., and Michael Camilleri, M.D.

From the Gastroenterology Division, Beth Israel Deaconess Medical Center, Boston (A.L.); and the Gastroenterology Division, Mayo Clinic, Rochester, Minn. (M.C.). Address reprint requests to Dr. Lembo at the Gastroenterology Division, Beth Israel Deaconess Medical Center, Dana 501, 330 Brookline Ave., Boston, MA 02215, or at alembo@bidmc.harvard.edu.

N Engl J Med 2003;349:1360-8.

Copyright © 2003 Massachusetts Medical Society.

CONSTIPATION IS A COMMON SYMPTOM AFFECTING BETWEEN 2 PERCENT^{1,2} and 27 percent³ of the population in Western countries. In the United States, it results in more than 2.5 million visits to physicians, 92,000 hospitalizations,² and laxative sales of several hundred million dollars a year. Constipation is more prevalent in women than in men,⁴ in nonwhites than in white persons,⁵ in children than in adults,⁶ and in elderly than in younger adults.⁵ Severe constipation (e.g., bowel movements only twice a month) is seen almost exclusively in women.⁴ Physical inactivity, low income, limited education, a history of sexual abuse, and symptoms of depression are all risk factors for constipation.⁷

Though the symptoms associated with constipation are often intermittent and mild, they may be chronic, difficult to treat, and debilitating. This review focuses on the evaluation and treatment of patients whose constipation is chronic and severe and does not resolve with the use of simple dietary or therapeutic measures. An understanding of the physiological processes involved in colonic transit and defecation is important for the effective management of constipation.

DEFINITION

There is no single definition of constipation. Most patients define constipation by one or more symptoms: hard stools, infrequent stools (typically fewer than three per week), the need for excessive straining, a sense of incomplete bowel evacuation, and excessive time spent on the toilet or in unsuccessful defecation.^{8,9} An epidemiologic study of constipation in the United States identified it as an inability to evacuate stool completely and spontaneously three or more times per week.¹ A consensus definition of constipation (the Rome II criteria), used in current research, is shown in Table 1.¹⁰

CAUSES AND PATHOPHYSIOLOGY

Constipation is frequently multifactorial and can result from systemic or neurologic disorders or medications. Constipation can be classified into three broad categories: normal-transit constipation, slow-transit constipation, and disorders of defecatory or rectal evacuation. More than one mechanism may contribute to constipation in a patient. In a study of more than 1000 patients with chronic constipation, normal transit through the colon was the most prevalent form (occurring in 59 percent of the patients), followed by defecatory disorders (25 percent), slow transit (13 percent), and a combination of defecatory disorders and slow transit (3 percent).⁶

Normal-Transit Constipation

Normal-transit constipation (or "functional" constipation) is the most common form of constipation that clinicians see. In patients with this disorder, stool traverses at a normal rate through the colon and the stool frequency is normal, yet patients believe they are constipated.¹¹ In this group of patients, constipation is likely to be due to a perceived difficul-

ty with evacuation or the presence of hard stools. The patients may experience bloating and abdominal pain or discomfort, and they may exhibit increased psychosocial distress¹¹; some may have increased rectal compliance, reduced rectal sensation, or both.¹² Symptoms of constipation typically respond to therapy with dietary fiber alone or with the addition of an osmotic laxative.¹³ Lack of a response to these therapies may reflect a disturbance of evacuation or transit that requires further management.

Defecatory Disorders

Defecatory disorders are most commonly due to dysfunction of the pelvic floor or anal sphincter. Other terms used to describe defecatory disorders include anismus, pelvic-floor dyssynergia, paradoxical pelvic-floor contraction, obstructed constipation, functional rectosigmoid obstruction, the spastic pelvic-floor syndrome, and functional fecal retention in childhood. Functional fecal retention in children may result in secondary encopresis¹⁴ due to leakage of liquid stool around impacted stool, which can lead to an initial misdiagnosis of diarrhea.

Prolonged avoidance of the pain associated with either the passage of a large, hard stool or an anal fissure or hemorrhoid may result in defecatory disorders.¹⁵ Structural abnormalities, such as rectal intussusception, rectocele, obstructing sigmoidocele, and excessive perineal descent, are less common causes of defecatory disorders. Some patients have a history of sexual or physical abuse or an eating disorder. Failure of the rectum to empty effectively may be due to an inability to coordinate the abdominal, rectoanal, and pelvic-floor muscles during defecation.^{16,17} These dysfunctions can be identified clinically and with the use of defecography as reduced descent of the perineum (less than 1 cm) and a reduced change in the anorectal angle (usually less than 15 degrees) during simulation of straining to defecate (Fig. 1). Ignoring or suppressing the urge to defecate may contribute to the development of mild constipation¹⁸ before the evacuation disorder becomes severe.

Slow-Transit Constipation

Slow-transit constipation occurs most commonly¹⁹ in young women who have infrequent bowel movements (once a week or fewer). The condition often starts at puberty. Associated symptoms are an infrequent urge to defecate, bloating, and abdominal pain or discomfort.

In patients with a minimal delay in colonic trans-

Table 1. Rome II Criteria for Constipation.

Adults

Two or more of the following for at least 12 weeks (not necessarily consecutive) in the preceding 12 months:

Straining during >25% of bowel movements

Lumpy or hard stools for >25% of bowel movements

Sensation of incomplete evacuation for >25% of bowel movements

Sensation of anorectal blockage for >25% of bowel movements

Manual maneuvers to facilitate >25% of bowel movements (e.g., digital evacuation or support of the pelvic floor)

<3 Bowel movements per week

Loose stools not present, and insufficient criteria for irritable bowel syndrome met¹⁰

Infants and children

Pebble-like, hard stools for a majority of bowel movements for at least 2 weeks

Firm stools ≤ 2 times per week for at least 2 weeks

No evidence of structural, endocrine, or metabolic disease

it, dietary and cultural factors contribute to symptoms. In these patients, a high-fiber diet may increase stool weight, decrease colon-transit time, and relieve constipation. Patients with more severe slow-transit constipation have a poor response to dietary fiber^{13,19} and laxatives. Such patients have more delayed emptying of the proximal colon²⁰ and fewer high-amplitude peristaltic contractions after meals, which normally induce movement of content through the colon. Colonic inertia, a related condition, is characterized by slow colonic transit and the lack of an increase in motor activity after meals or after the administration of bisacodyl,²¹ cholinergic agents, or anticholinesterases such as neostigmine.²²

Histopathological studies in patients with slow-transit constipation have shown alterations in the number of myenteric plexus neurons expressing the excitatory neurotransmitter substance P,²³ abnormalities in the inhibitory transmitters vasoactive intestinal peptide and nitric oxide,²⁴ and a reduction in the number of interstitial cells of Cajal,²⁵ which are thought to regulate gastrointestinal motility.

Hirschsprung's disease is an extreme form of slow-transit constipation with similar enteric neuropathological features. In Hirschsprung's disease, ganglion cells in the distal bowel are absent, a result of an arrest in the caudal migration of neural-crest cells through the gut during embryonic development; the bowel narrows at the area that lacks ganglion cells. Though most patients with this disorder




Figure 1. Sagittal View of the Anorectum at Rest (Panel A) and during Straining to Defecate (Panel B).

Continence is maintained by normal rectal sensation and tonic contraction of the internal anal sphincter and the puborectalis muscle, which wraps around the anorectum, maintaining an anorectal angle between 80 and 110 degrees. During defecation, the pelvic-floor muscles (including the puborectalis) relax, allowing the anorectal angle to straighten by at least 15 degrees, and the perineum descends by 1.0 to 3.5 cm. The external anal sphincter also relaxes and reduces pressure on the anal canal.

present in infancy or early childhood, some patients with a relatively short segment of colon involved do not have symptoms until later in life.²⁶ Hirschsprung's disease is associated with mutations in the RET proto-oncogene or the gene for the endothelin-B receptor.²⁷

CLINICAL EVALUATION

HISTORY AND PHYSICAL EXAMINATION

A thorough history taking and physical examination can rule out most secondary causes of constipation. An assessment of stool form can be used to estimate the extremes of colonic transit time, since very loose or hard stools are correlated with rapid or slow colonic transit, respectively.²⁸

A careful rectal examination should be performed in every patient with constipation and is often the most revealing part of the clinical evaluation. First, the perianal area should be examined for scars, fistulas, fissures, and the presence of external hemorrhoids. Next, the clinician should observe the perineum with the patient at rest and then while the

patient is bearing down, in order to determine the extent of perineal descent, which is normally between 1.0 and 3.5 cm (Fig. 1). Reduced descent may indicate an inability to relax the pelvic-floor muscles during defecation. Excessive perineal descent (below the plane of the ischial tuberosities or exceeding 3.5 cm) may indicate laxity of the perineum, which usually results from childbirth or many years of excessive straining during defecation and may lead to incomplete evacuation. Eventually, the stretching of the pelvic floor associated with excessive descent may injure the sacral nerves, reducing rectal sensation and resulting in incontinence.²⁹

Finally, a digital examination of the rectum should be performed to determine whether fecal impaction, anal stricture, or rectal masses are present. A patulous anal sphincter may suggest trauma or a neurologic disorder as the cause of impaired sphincter function. Other important functions that should be assessed during the digital rectal examination are summarized in Table 2. Difficulty inserting the finger into the anal canal or the inability to do so suggests elevated pressure of the anal sphincter at rest

or anal stricture. Tenderness of the posterior aspect of the rectum may suggest a spasm of the pelvic floor.

LABORATORY TESTS

Laboratory tests that may be useful in patients with constipation include thyroid-function tests; measurements of calcium, glucose, and electrolytes; a complete blood count; and urinalysis. A complete examination of the colon is required to exclude the possibility of structural diseases such as colon cancer when there are so-called alarm symptoms (e.g., a new onset or worsening of constipation, blood in the stools, weight loss, fevers, anorexia, nausea, vomiting, or a family history of inflammatory bowel disease or colon cancer). In patients without alarm symptoms who are younger than 50 years of age, sigmoidoscopy is sufficient. However, all adults older than 50 who present with constipation should undergo colonoscopy or both sigmoidoscopy and barium-enema examination to screen for colorectal cancer.³⁰

PHYSIOLOGICAL EXAMINATION

Physiological testing is necessary only in patients with refractory symptoms who do not have a secondary cause of constipation or in whom a trial of a high-fiber diet and laxatives was not effective. In patients with physical findings or symptoms suggestive of a defecatory disorder, the initial physiological tests to consider are anorectal manometry and balloon expulsion. Defecography may be considered if the results of these tests are equivocal or if there is a clinical suspicion of a structural abnormality in the rectum that impedes defecation (e.g., rectal prolapse). Delayed colonic transit can result from a defecatory disorder, and measurement of the colonic transit time should therefore be considered after the underlying pelvic-floor dysfunction has been corrected.

In patients without clinical features that suggest a defecatory disorder, the initial physiological test to consider is measurement of the colonic transit time, to distinguish slow-transit constipation from normal-transit constipation. The anorectal manometry and balloon-expulsion tests should be considered for patients who do not have a response to treatment with fiber and laxatives.

Colonic-Transit Testing

The colonic transit time is normally less than 72 hours. It is measured by performing abdominal ra-

Table 2. Diagnostic Findings in Patients with Defecatory Disorders.

History

- Prolonged straining to expel stool
- Unusual postures on the toilet to facilitate stool expulsion
- Support of the perineum, digitation of rectum, or posterior vaginal pressure to facilitate rectal emptying
- Inability to expel enema fluid
- Constipation after subtotal colectomy for constipation

Rectal examination (with patient in left lateral position)

Inspection

- Anus pulled forward while the patient is bearing down
- Anal verge descends <1.0 cm or >3.5 cm (or beyond the ischial tuberosities) while the patient is bearing down
- Perineum balloons down while the patient is bearing down, and rectal mucosa partially prolapses through anal canal

Palpation

- High anal-sphincter tone at rest
- Anal-sphincter pressure during voluntary contraction is only slightly higher than tone at rest
- Perineum and examining finger descend <1.0 cm or >3.5 cm while patient simulates straining during defecation
- Puborectalis muscle is tender on palpation through the rectal wall posteriorly, or palpation reproduces pain
- Palpable mucosal prolapse during straining
- Defect in anterior wall of the rectum, suggestive of rectocele

Anorectal manometry and balloon expulsion (with patient in left lateral position)

- Average tone of anal sphincter at rest, >80 cm water (or >60 mm Hg)
- Average pressure of anal sphincter during contraction, >240 cm water (or >180 mm Hg)
- Failure to expel balloon

diography 120 hours after the patient has ingested radiopaque markers in a gelatin capsule (such as Sitz-Mark, Konsyl Pharmaceuticals).³¹ Before the study, the patient should be on a high-fiber diet but should not take laxatives, enemas, or medications that may affect bowel function. Retention of more than 20 percent of the markers indicates prolonged transit. If the markers are retained exclusively in the lower left colon and rectum, the patient may have a defecatory disorder, although retention of markers throughout the colon does not rule out a defecatory disorder.

Anorectal Manometry

Anorectal manometry provides several important measurements: the pressure of the anal sphincter at rest (predominantly the internal anal sphincter) and the maximal voluntary contraction of the exter-

Table 3. Medications Commonly Used for Constipation.

Medication	Maximal Recommended Dose	Comments
Bulk laxative		
Psyllium (Metamucil, Perdiem, Fiberall)	Titrate up to ~20 g	Increases colonic residue, stimulating peristalsis Natural fiber that undergoes bacterial degradation, which may contribute to bloating and flatus; should be taken with plenty of water to avoid intestinal obstruction; allergic reactions such as anaphylaxis and asthma are rare
Methylcellulose (Citrucel)	Titrate up to ~20 g	Semisynthetic cellulose fiber that is relatively resistant to colonic bacterial degradation
Polycarbophil (Fibercon, Equalactin, Konsyl)	Titrate up to ~20 g	Synthetic fiber of polymer of acrylic acid, resistant to bacterial degradation
Osmotic laxative		
Draws water into the intestines along osmotic gradient		
Saline laxatives		
Magnesium hydroxide (Phillips' Milk of Magnesia)	15–30 ml once or twice a day	A small percentage of magnesium is actively absorbed in the small intestines; hypermagnesemia can occur in patients with renal failure and in children Hyperphosphatemia can occur in patients with renal insufficiency; commonly used for bowel preparation before colonoscopy
Magnesium citrate (Evac-Q-Mag)	150–300 ml as needed	
Sodium phosphate (Fleet Enema, Fleet Phospho-Soda, Visicol)	10–25 ml with 12 oz (360 ml) of water as needed	
Poorly absorbed sugar		
Lactulose (Cephulac, Chronulac, Duphalac)	15–30 ml once or twice a day	Synthetic disaccharide consisting of galactose and fructose linked by bond resistant to disaccharidases; not absorbed by the small intestine; undergoes bacterial fermentation in the colon with formation of short-chain fatty acids; gas and bloating are common side effects
Sugar alcohols		
Sorbitol (Cystosol) Mannitol	15–30 ml once or twice a day	Poorly absorbed by intestine; undergoes bacterial fermentation
Polyethylene glycol and electrolytes (Colyte, GoLYTELY, NuLYTELY)	17–36 g once or twice a day	Organic polymers that are poorly absorbed and not metabolized by colonic bacteria and may therefore cause less bloating and cramping than other poorly absorbed sugars ⁴⁰ ; can be mixed with noncarbonated beverages
Polyethylene glycol 3350 (Miralax)	17–36 g once or twice a day	Does not include electrolytes and is packaged for more regular use
Stimulant laxative		
Stimulates intestinal motility or secretion		
Anthraquinones		
Cascara sagrada (Colamin, Sagrada-lax)	325 mg (or 5 ml) daily	Converted by colonic bacteria to their active form; may cause melanosis coli, a benign condition that is usually reversible within 12 months after the cessation of laxative use; no definitive association between anthraquinones and colon cancer or myenteric nerve damage has been established
Senna (Senokot, Ex-Lax)	187 mg daily	
Castor oil (Purge, Neoloid, Emulsoil)	15–30 ml daily	Hydrolyzed by lipase in the small intestine to ricinoleic acid, which inhibits intestinal water absorption, increases mucosal permeability, and stimulates motor function through the release of neurotransmitters from mucosal enterochromaffin cells; cramping and severe diarrhea are common
Diphenylmethane derivatives		
Bisacodyl (Dulcolax, Correctol)	5–10 mg every night	Hydrolyzed by endogenous esterases; stimulates secretion and motility of small intestine and colon
Sodium picosulfate (Lubrilax, Sur-lax)	5–15 mg every night	Hydrolyzed to its active form by colonic bacterial enzymes; affects only the colon
Stool softener		
Docusate sodium (Colace, Regulax SS, Surfak)	100 mg twice a day	Ionic detergents soften stool by allowing water to interact more effectively with solid stool; modest fluid secretion; efficacy for treatment is not well established
Mineral oil (Fleet Mineral Oil)	5–15 ml orally every night	An emollient providing lubrication for the passage of stool; long-term use can cause malabsorption of fat-soluble vitamins and anal seepage; lipid pneumonia can occur in patients predisposed to aspiration of liquids

Table 3. (Continued.)

Medication	Maximal Recommended Dose	Comments
Rectal enema or suppository		
Phosphate enema (Fleet Enema)	120 ml daily	Initiates evacuation by distending the rectum, softening hard stool, and topically stimulating the colonic muscle to contract ⁴¹ ; hyperphosphatemia and other electrolyte abnormalities can occur if the enema is retained
Mineral-oil-retention enema (Fleet Mineral Oil Enema)	100 ml daily	
Tap-water enema	500 ml daily	
Soapsuds enema	1500 ml daily	
Glycerin bisacodyl suppository	10 mg daily	
Cholinergic agent		
Bethanechol (Urecholine)	10 mg daily	Appears to be beneficial in patients with constipation due to tricyclic antidepressants ⁴² ; intravenous neostigmine, a cholinesterase inhibitor, is effective in decompressing the colon in patients with acute colonic pseudo-obstruction ⁴³ but has not been evaluated in patients with chronic constipation
Miscellaneous		
Colchicine (Colsalide)	0.6 mg 3 times a day	Data for both medications are limited, ^{44,45} and side effects are common; therefore, they are not recommended
Misoprostol (Cytotec)	600–2400 µg daily	
Prokinetic agent		
5-HT ₄ -receptor agonists*		Stimulation of 5-HT ₄ receptors in the intestines induces peristalsis ⁴⁶ ; cisapride, a substituted benzamide, had variable results in treating constipation ⁴⁷ ; potentially lethal cardiac dysrhythmias led to its removal from the commercial market; tegaserod, a partial 5-HT ₄ agonist, is an aminoguanidine indole derivative of serotonin that reduces pain and bloating, increases the frequency of bowel movements, and improves their consistency in women with constipation-predominant irritable bowel syndrome ⁴⁸
Cisapride (Propulsid)†	10–20 mg 4 times a day	
Tegaserod (Zelnorm)	6 mg twice a day	

* 5-HT₄ denotes 5-hydroxytryptamine₄.

† This is available only through a limited-access program developed by Janssen Pharmaceutica and the Food and Drug Administration.

nal sphincter, the presence or absence of relaxation of the internal anal sphincter during balloon distention (the anorectal inhibitory reflex), rectal sensation, and the ability of the anal sphincters to relax during straining.^{32,33} Patients with defecatory disorders commonly have inappropriate contraction of the anal sphincter at rest and while bearing down. The absence of the anorectal inhibitory reflex suggests the possibility of Hirschsprung's disease. However, in the majority of patients, lack of the reflex is due to enlargement of the rectum from retained stool and insufficient distention of the rectal wall by the distended balloon. A high anal pressure at rest and rectal pain suggest the presence of an anal fissure, or anismus, since a fissure causes a voluntary contraction by the external sphincter, which augments the resting pressure. Rectal hyposensitivity (suggested by an increase in the volume of balloon distention required to induce urgency) may suggest a neurologic disorder, but more frequently it results from increased rectal capacity due to prolonged retention of stool.

Balloon Expulsion

Balloon expulsion is a simple, office-based screening test for defecatory disorders. After insertion of the latex balloon into the rectum, 50 ml of water or air is instilled into the balloon, and the patient is asked to expel the balloon into a toilet. Inability to expel the balloon within two minutes suggests a defecatory disorder.³⁴ In some laboratories, balloon evacuation is performed in the left lateral position and weights are added to the rectal catheter over a pulley device to facilitate defecation. Normally, expulsion in the left lateral position can be achieved spontaneously or with the addition of less than 200 g of weight.³²

Defecography

Defecography is performed by instilling thickened barium into the rectum. With the patient sitting on a radiolucent commode, radiographic films or videos are taken during fluoroscopy while the patient is resting, contracting the anal sphincter, and straining to defecate. This procedure is used to determine

whether complete emptying of the rectum has been achieved, to measure the anorectal angle and perineal descent, and to detect structural abnormalities that may impede defecation, such as a rectocele, internal mucosal prolapse, or intussusception.

A rectocele represents a herniation, usually of the anterior rectal wall toward the vagina, and it usually results from trauma during childbirth or episiotomy.³⁵ Paradoxical sphincter contraction is frequently encountered in patients with rectocele, suggesting that straining against a spastic pelvic floor may facilitate development of the rectocele. A rectocele is clinically significant only if it fills preferentially or if it fails to empty after simulated defecation.

MANAGEMENT

Increases in fluid intake and physical activity do not appear to relieve chronic constipation, except in patients who are dehydrated.^{36,37} Patients with normal-transit or slow-transit constipation should increase their fiber intake to 20 to 25 g per day, either with changes in their diet or with commercial fiber supplements. Patients who do not have a response to fiber therapy should try an osmotic laxative such as milk of magnesia, sorbitol, lactulose, or polyethylene glycol. The dose of the osmotic laxative should be adjusted until soft stools are attained. Colonic stimulants, such as bisacodyl or senna derivatives, and prokinetic medications, such as tegaserod, a partial 5-hydroxytryptamine₄-receptor agonist, should be reserved for patients with severe constipation who do not have a response to fiber or osmotic laxatives. Surgery is rarely necessary.

Patients with defecatory disorders should undergo retraining of the evacuation process with the assistance of biofeedback.³⁸ Patients with severe defecatory disorders often do not have a good response to oral laxatives unless they are taken at relatively high doses, which may result in watery diarrhea and other adverse effects.

Patients with fecal impaction should have the impacted feces removed manually or, if necessary, with enemas.³⁹ Further episodes of fecal impaction should be prevented with sufficient fiber intake and use of laxatives to induce regular bowel movements.

FIBER

Patients' compliance with the use of fiber supplements is poor because of their side effects, which include flatulence, distention, bloating, and unpleasant taste. To improve compliance, patients should

be instructed to increase their dietary fiber intake gradually to 20 to 25 g per day over a period of one to two weeks. Initially, foods rich in dietary fiber (such as fruits and vegetables) should be increased. If this approach is not effective, commercially packaged fiber supplements should be tried (Table 3).

LAXATIVES

Osmotic laxatives are poorly absorbed or nonabsorbed substances that result in the secretion of water in the intestines to maintain isotonicity with plasma (Table 3). Most osmotic laxatives take several days to work. In patients with renal insufficiency or cardiac dysfunction, osmotic laxatives may cause electrolyte and volume overload from absorption of sodium, magnesium, or phosphorus. Dehydration can occur when osmotic laxatives are overused.

Stimulant laxatives increase intestinal motility and secretions. They work within hours and may cause abdominal cramps. Although stimulant laxatives have been reported to cause a so-called cathartic colon (often described as the loss of haustration and dilatation of the colon), data do not support this theory.²³ However, melanosis coli, a brown-black pigmentation of the colonic mucosa, may develop in patients who take stimulant laxatives containing anthraquinones.⁴⁹ The pigmentation is due to the accumulation of apoptotic epithelial cells in the colon that have been phagocytosed by macrophages. Melanosis coli does not lead to the development of colon cancer⁵⁰ or other abnormalities in the colon, and if the patient stops taking the stimulant laxative, the condition decreases over time.

PROKINETIC DRUGS

Tegaserod is a colonic prokinetic agent that improves stool consistency and frequency in women with irritable bowel syndrome characterized by constipation.⁴⁸

BIOFEEDBACK THERAPY

During biofeedback for constipation due to defecatory disorders, patients receive visual and auditory feedback, or both, on the functioning of their anal-sphincter and pelvic-floor muscles. Biofeedback can be used to train patients to relax their pelvic-floor muscles during straining and to coordinate this relaxation with abdominal maneuvers to enhance the entry of stool into the rectum. Biofeedback can be performed with anorectal electromyography or a manometry catheter. Simulated evacuation with a

balloon or silicon-filled artificial stool, called "fecom,"⁵¹ is commonly used to emphasize normal coordination for successful defecation. Patient education and the development of a rapport between the therapist and the patient are key to successful biofeedback.⁵²

A systematic review of biofeedback studies revealed an overall success rate of 67 percent, although data from controlled studies are lacking.³⁸ The benefits of biofeedback appear to be long-lasting. Biofeedback may be less effective for patients with the descending perineum syndrome than for patients with other defecatory disorders.²⁹

BOTULINUM TYPE A TOXIN

Preliminary data⁵³ suggest that injection of botulinum type A toxin into the puborectalis muscle may be effective in the treatment of defecatory disorders involving spastic pelvic-floor muscles. However, since controlled trials have not yet been performed, this approach is not recommended over biofeedback, for which there is more evidence of efficacy and more clinical experience.

SURGERY

For refractory constipation, total colonic resection and ileorectostomy should be considered only if the patient does not have a defecatory disorder and only after medical therapies have failed. Colonic resec-

tion is generally reserved for patients with slow-transit constipation.

A review of 32 studies showed that between 39 percent and 100 percent of patients were satisfied after colectomy.⁵⁴ The most common complications after surgery were obstruction of the small bowel, diarrhea, and incontinence. However, the diarrhea and incontinence improved after the first year.²⁰ Patients with upper-gut dysmotility (e.g., gastroparesis or pseudo-obstruction) or psychological disturbances do not fare as well.⁵⁵ Preliminary reports suggest that for those in whom colonic resection is deemed appropriate, laparoscopic subtotal colectomy is as effective as laparotomy.⁵⁶

Rectal surgery should be considered only in patients with functionally significant rectoceles and in women whose constipation is relieved with application of digital vaginal pressure to facilitate defecation.⁵⁷

Supported in part by grants from the National Institutes of Health (R01AT001414, to Dr. Lembo; R01 DK54681 and K24 DK02638, to Dr. Camilleri).

Dr. Camilleri reports having received consulting fees from Johnson and Johnson, TAP, Takeda, and Yamanouchi and grant support from Alizyme, GlaxoSmithKline, Janssen, Johnson and Johnson, Merck, and VSL. Dr. Lembo reports having received consulting fees from Janssen Pharmaceutical and Schwartz Pharmaceutical and lecture fees and grant support from AstraZeneca and Janssen Pharmaceutical.

We are indebted to Dr. Ciaran Kelly for review of the manuscript and to Tracey Lembo for editorial assistance.

REFERENCES

1. Stewart WF, Liberman JN, Sandler RS, et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. *Am J Gastroenterol* 1999;94:3530-40.
2. Sonnenberg A, Koch TR. Physician visits in the United States for constipation: 1958 to 1986. *Dig Dis Sci* 1989;34:606-11.
3. Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. *Am J Gastroenterol* 2001;96:3130-7.
4. Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon FE, Hughes AO. Defecation frequency and timing, and stool form in the general population: a prospective study. *Gut* 1992;33:818-24.
5. Johanson JF, Sonnenberg A, Koch TR. Clinical epidemiology of chronic constipation. *J Clin Gastroenterol* 1989;11:525-36.
6. Nyam DC, Pemberton JH, Ilstrup DM, Rath DM. Long-term results of surgery for chronic constipation. *Dis Colon Rectum* 1997;40:273-9. [Erratum, *Dis Colon Rectum* 1997;40:529.]
7. Everhart JE, Go VL, Johannes RS, Fitzsimmons SC, Roth HP, White LR. A longitudinal survey of self-reported bowel habits in the United States. *Dig Dis Sci* 1989;34:1153-62.
8. Sandler RS, Drossman DA. Bowel habits in young adults not seeking health care. *Dig Dis Sci* 1987;32:841-5.
9. Koch A, Voderholzer WA, Klauser AG, Muller-Lissner S. Symptoms in chronic constipation. *Dis Colon Rectum* 1997;40:902-6.
10. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. *Gut* 1999;45:Suppl 2:II-43-II-47.
11. Ashraf W, Park F, Lof J, Quigley EM. An examination of the reliability of reported stool frequency in the diagnosis of idiopathic constipation. *Am J Gastroenterol* 1996;91:26-32.
12. Mertz H, Naliboff B, Mayer E. Physiology of refractory chronic constipation. *Am J Gastroenterol* 1999;94:609-15.
13. Voderholzer WA, Schatke W, Muhldorfer BE, Klauser AG, Birkner B, Muller-Lissner SA. Clinical response to dietary fiber treatment of chronic constipation. *Am J Gastroenterol* 1997;92:95-8.
14. Doig CM. ABC of colorectal diseases: paediatric problems. *BMJ* 1992;305:462-4.
15. Loening-Baucke V. Encopresis and soiling. *Pediatr Clin North Am* 1996;43:279-98.
16. Camilleri M, Thompson WG, Flesherman JW, Pemberton JH. Clinical management of intractable constipation. *Ann Intern Med* 1994;121:520-8.
17. Rao SS, Welcher KD, Leistikow JS. Obstructive defecation: a failure of rectoanal coordination. *Am J Gastroenterol* 1998;93:1042-50.
18. Klauser AG, Voderholzer WA, Heinrich CA, Schindlbeck NE, Muller-Lissner SA. Behavioral modification of colonic function: can constipation be learned? *Dig Dis Sci* 1990;35:1271-5.
19. Preston DM, Lennard-Jones JE. Severe chronic constipation of young women: 'idiopathic slow transit constipation.' *Gut* 1986;27:41-8.
20. Stivland T, Camilleri M, Vassallo M, et al. Scintigraphic measurement of regional gut transit in idiopathic constipation. *Gastroenterology* 1991;101:107-15.
21. O'Brien AD, Camilleri M, von der Ohe MR, et al. Motility and tone of the left colon

- in constipation: a role in clinical practice? *Am J Gastroenterol* 1996;91:2532-8.
22. Bassotti G, Chiarioni G, Imbimbo BP, et al. Impaired colonic motor response to cholinergic stimulation in patients with severe chronic idiopathic (slow transit type) constipation. *Dig Dis Sci* 1993;38:1040-5.
 23. Tzavella K, Riepl RL, Klauser AG, Voderholzer WA, Schindlbeck NE, Muller-Lissner SA. Decreased substance P levels in rectal biopsies from patients with slow transit constipation. *Eur J Gastroenterol Hepatol* 1996;8:1207-11.
 24. Cortesini C, Cianchi F, Infantino A, Lise M. Nitric oxide synthase and VIP distribution in enteric nervous system in idiopathic chronic constipation. *Dig Dis Sci* 1995;40:2450-5.
 25. He CL, Burgart L, Wang L, et al. Decreased interstitial cell of Cajal volume in patients with slow-transit constipation. *Gastroenterology* 2000;118:14-21.
 26. Barnes PR, Lennard-Jones JE, Hawley PR, Todd IP. Hirschsprung's disease and idiopathic megacolon in adults and adolescents. *Gut* 1986;27:534-41.
 27. Edery P, Pelet A, Mulligan LM, et al. Long segment and short segment familial Hirschsprung's disease: variable clinical expression at the RET locus. *J Med Genet* 1994;31:602-6.
 28. Degen LP, Phillips SF. How well does stool form reflect colonic transit? *Gut* 1996;39:109-13.
 29. Harewood GC, Coulie B, Camilleri M, Rath-Harvey D, Pemberton JH. Descending perineum syndrome: audit of clinical and laboratory features and outcome of pelvic floor retraining. *Am J Gastroenterol* 1999;94:126-30.
 30. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. *N Engl J Med* 2001;345:555-60.
 31. Hinton JM, Lennard-Jones JE, Young AC. A new method for studying gut transit times using radioopaque markers. *Gut* 1969;10:842-7.
 32. Pezim ME, Pemberton JH, Levin KE, Litchy WJ, Phillips SF. Parameters of anorectal and colonic motility in health and in severe constipation. *Dis Colon Rectum* 1993;36:484-91.
 33. Diamant NE, Kamm MA, Wald A, Whitehead WE. AGA technical review on anorectal testing techniques. *Gastroenterology* 1999;116:735-60.
 34. Fleshman JW, Dreznik Z, Cohen E, Fry RD, Kodner JJ. Balloon expulsion test facilitates diagnosis of pelvic floor outlet obstruction due to nonrelaxing puborectalis muscle. *Dis Colon Rectum* 1992;35:1019-25.
 35. Richardson AC. The rectovaginal septum revisited: its relationship to rectocele and its importance in rectocele repair. *Clin Obstet Gynecol* 1993;36:976-83.
 36. Young RJ, Beerman LE, Vanderhoof JA. Increasing oral fluids in chronic constipation in children. *Gastroenterol Nurs* 1998;21:156-61.
 37. Meshkinpour H, Selod S, Movahedi H, Nami N, James N, Wilson A. Effects of regular exercise in management of chronic idiopathic constipation. *Dig Dis Sci* 1998;43:2379-83.
 38. Enck P. Biofeedback training in disordered defecation: a critical review. *Dig Dis Sci* 1993;38:1953-60.
 39. Wrenn K. Fecal impaction. *N Engl J Med* 1989;321:658-62.
 40. Corazziari E, Badiali D, Habib FI, et al. Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. *Dig Dis Sci* 1996;41:1636-42.
 41. Flig E, Hermann TW, Zabel M. Is bisacodyl absorbed at all from suppositories in man? *Int J Pharm* 2000;196:11-20.
 42. Everett HC. The use of bethanechol chloride with tricyclic antidepressants. *Am J Psychiatry* 1975;132:1202-4.
 43. Ponc RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. *N Engl J Med* 1999;341:137-41.
 44. Verne GN, Eaker EY, Davis RH, Sninsky CA. Colchicine is an effective treatment for patients with chronic constipation: an open-label trial. *Dig Dis Sci* 1997;42:1959-63.
 45. Roarty TP, Weber F, Soykan I, McCallum RW. Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial. *Aliment Pharmacol Ther* 1997;11:1059-66.
 46. Grider JR, Fox-Orenstein AE, Jin JG. 5-Hydroxytryptamine₄ receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. *Gastroenterology* 1998;115:370-80.
 47. Krevsky B, Maurer AH, Malmud LS, Fisher RS. Cisapride accelerates colonic transit in constipated patients with colonic inertia. *Am J Gastroenterol* 1989;84:882-7.
 48. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT₄ receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. *Aliment Pharmacol Ther* 2001;15:1655-66.
 49. Badiali D, Marcheggiano A, Pallone F, et al. Melanosis of the rectum in patients with chronic constipation. *Dis Colon Rectum* 1985;28:241-5.
 50. van Gorkom BA, de Vries EG, Karrenbeld A, Kleibeuker JH. Anthranoid laxatives and their potential carcinogenic effects. *Aliment Pharmacol Ther* 1999;13:443-52.
 51. Pelsang RE, Rao SS, Welcher K. FECOM: a new artificial stool for evaluating defecation. *Am J Gastroenterol* 1999;94:183-6.
 52. Koutsomanis D, Lennard-Jones JE, Roy AJ, Kamm MA. Controlled randomised trial of visual biofeedback versus muscle training without a visual display for intractable constipation. *Gut* 1995;37:95-9.
 53. Ron Y, Avni Y, Lukovetski A, et al. Botulinum toxin type-A in therapy of patients with anismus. *Dis Colon Rectum* 2001;44:1821-6.
 54. Knowles CH, Scott M, Lunniss PJ. Outcome of colectomy for slow transit constipation. *Ann Surg* 1999;230:627-38.
 55. Redmond JM, Smith GW, Barofsky I, Ratych RE, Goldsborough DC, Schuster MM. Physiological tests to predict long-term outcome of total abdominal colectomy for intractable constipation. *Am J Gastroenterol* 1995;90:748-53.
 56. Young-Fadok TM. Raising the bar: laparoscopic resection of colorectal cancer. *Surg Endosc* 2001;15:911-2.
 57. Sarles JC, Arnaud A, Selezneff I, Olivier S. Endo-rectal repair of rectocele. *Int J Colorectal Dis* 1989;4:167-71.

Copyright © 2003 Massachusetts Medical Society.

Copyright 2003. Massachusetts Medical Society.
Reproduced by permission. Further reproduction
prohibited without consent of authors and
publisher.